AKANTIOR (Polihexanide) Eye Drops
Antiparasitic eye drops for the treatment of Acanthamoeba keratitis
📊 Quick Facts About AKANTIOR
💡 Key Takeaways About AKANTIOR
- First approved treatment for Acanthamoeba keratitis: AKANTIOR is the first and only medicine specifically licensed in the EU for treating this rare parasitic eye infection
- Dual mechanism of action: Polihexanide works by destroying the Acanthamoeba cell membrane and preventing DNA replication, targeting both active trophozoites and dormant cysts
- Intensive treatment schedule required: Treatment starts with hourly drops (16 times/day) for the first 5 days, gradually tapering over 19 days, followed by maintenance therapy
- Most common side effects are eye pain and redness: These occur in more than 1 in 10 users and are generally mild to moderate in the treated eye
- Preservative-free single-dose containers: Each container is for single use only; discard immediately after use, even if solution remains
What Is AKANTIOR and What Is It Used For?
AKANTIOR is a prescription eye drop containing polihexanide (PHMB) at a concentration of 0.8 mg/mL. It is approved for the treatment of Acanthamoeba keratitis in adults and children aged 12 years and older. Acanthamoeba keratitis is a rare but potentially sight-threatening parasitic infection of the cornea.
Acanthamoeba keratitis (AK) is caused by Acanthamoeba, a genus of free-living amoebae found ubiquitously in the environment — in soil, fresh water, tap water, and even in swimming pools and hot tubs. These microscopic organisms can infect the cornea, the transparent layer at the front of the eye, leading to severe inflammation and potentially devastating damage to the corneal surface, including ulceration and perforation. The infection predominantly affects contact lens wearers, with an estimated 85–90% of cases in developed countries occurring in this population, particularly those who use improper lens hygiene practices or swim while wearing contacts.
Before the approval of AKANTIOR, there was no formally authorised medicine for Acanthamoeba keratitis. Treatment relied on off-label use of compounded formulations, typically combinations of biguanides (such as polihexamethylene biguanide or chlorhexidine) and diamidines (such as propamidine or hexamidine). These compounded preparations varied in concentration, sterility, and availability, creating significant challenges for patients and clinicians. AKANTIOR addresses this unmet medical need by providing a standardised, quality-controlled, preservative-free formulation that has undergone rigorous regulatory evaluation by the European Medicines Agency (EMA).
The active substance in AKANTIOR, polihexanide (also known as polyhexamethylene biguanide or PHMB), is a polymeric biguanide that has been used for decades as an antiseptic in wound care and as a disinfectant in contact lens solutions. In AKANTIOR, it is specifically formulated at the optimal concentration for ophthalmic use against Acanthamoeba. PHMB works through a dual mechanism of action: it damages the outer membrane of the Acanthamoeba organism, causing the contents of the parasite cell to leak out and thereby destroying it. Simultaneously, PHMB interferes with enzymes required for DNA replication, preventing the parasite from growing and multiplying. This dual action is critical because Acanthamoeba exists in two forms — an active trophozoite form that feeds and divides, and a dormant cyst form that is highly resistant to many antimicrobial agents.
Acanthamoeba keratitis typically presents with severe eye pain that is disproportionate to the clinical findings, tearing, light sensitivity (photophobia), redness, and progressive vision loss. The infection can be challenging to diagnose, as its symptoms can mimic other forms of keratitis, including herpes simplex or fungal keratitis. Early diagnosis and prompt initiation of treatment with effective antiparasitic therapy such as AKANTIOR are essential for achieving the best possible outcomes and preserving vision.
Acanthamoeba keratitis remains a rare condition, with an estimated incidence of 1–33 cases per million contact lens wearers per year in Europe. However, the impact on affected individuals can be severe, with potential outcomes including chronic pain, corneal scarring, and permanent vision loss requiring corneal transplantation. The availability of AKANTIOR as a licensed, standardised treatment represents an important advance in the management of this condition.
What Should You Know Before Using AKANTIOR?
AKANTIOR should not be used if you are allergic to polihexanide or any of the other ingredients. It is not recommended during pregnancy or in children under 12 years. If you use other eye drops, wait at least 5 minutes between applications, and always use AKANTIOR last.
Contraindications
Do not use AKANTIOR if you have a known allergy (hypersensitivity) to polihexanide or any of the other ingredients in this medicine. The inactive ingredients include sodium phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, and purified water. If you have previously experienced an allergic reaction to polihexanide-containing products (such as certain wound care solutions or contact lens disinfectants), inform your doctor before starting treatment.
Allergic reactions to polihexanide are uncommon but can occur. Signs of an allergic reaction may include increased redness, itching, swelling of the eyelids, or a rash around the eyes. If you experience any signs of an allergic reaction after using AKANTIOR, stop the treatment immediately and contact your healthcare provider.
Warnings and Precautions
Before starting treatment with AKANTIOR, discuss with your doctor or pharmacist any concerns you may have. Treatment with AKANTIOR can cause mild to moderate discomfort in the eyes, including eye pain and ocular hyperemia (red eyes). These are the most frequently reported side effects and are considered part of the expected response during treatment. However, if you experience a severe eye reaction, such as sudden worsening of vision, intense pain, or significant swelling, contact your healthcare provider promptly.
AKANTIOR contains phosphate. Each drop contains approximately 0.37 mg of phosphate, corresponding to 10.66 mg/mL. In patients with severely damaged corneas, phosphate may in very rare cases cause cloudy patches on the cornea due to calcium accumulation (corneal calcification) during treatment. Your ophthalmologist will monitor your corneal health throughout the treatment course.
It is important to complete the full course of treatment as prescribed by your doctor. Acanthamoeba cysts are highly resistant organisms, and premature discontinuation of therapy can lead to recurrence of the infection, which may be more difficult to treat the second time. Your doctor will monitor your progress through regular follow-up examinations and will tell you when it is appropriate to stop treatment.
Your vision may become temporarily blurred after applying AKANTIOR eye drops. Do not drive a car or operate machinery until your vision has returned to normal. This effect is transient and typically resolves within minutes of application.
Pregnancy and Breastfeeding
There is no clinical experience with the use of AKANTIOR in pregnant women. As a precautionary measure, AKANTIOR is not recommended during pregnancy. If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using this medicine. Your doctor will assess whether the potential benefit of treating the infection outweighs any theoretical risk to the developing baby.
It is not known whether polihexanide is excreted in human breast milk. Given that AKANTIOR is administered as eye drops and systemic absorption is expected to be minimal, the risk to a breastfed infant is considered low. Nevertheless, consult your doctor or pharmacist before using AKANTIOR if you are breastfeeding. A decision will be made whether to discontinue breastfeeding or to continue treatment, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
Children and Adolescents
AKANTIOR is approved for use in adults and adolescents aged 12 years and older. It is not recommended for children under 12 years of age because it has not been studied in this age group. The safety and efficacy profile in younger children has not been established, and the dosing schedule has not been validated for paediatric patients under 12. If an ophthalmologist suspects Acanthamoeba keratitis in a child under 12, alternative treatment approaches should be discussed within a specialist setting.
How Does AKANTIOR Interact with Other Drugs?
If you are using other eye drops, wait at least 5 minutes between each product, and always apply AKANTIOR last. No significant systemic drug interactions have been identified for AKANTIOR due to its topical ophthalmic route of administration and minimal systemic absorption.
Inform your doctor or pharmacist about all medicines you are currently using, have recently used, or might use, including prescription and over-the-counter medicines, eye drops, and herbal products. Although no formal drug interaction studies have been conducted with AKANTIOR, there are practical considerations when using multiple ophthalmic medications simultaneously.
The primary concern with concomitant eye drop use is the physical interaction between different formulations in the tear film. When multiple eye drops are applied in rapid succession, the first drop may be diluted or washed away by the second, reducing the effectiveness of both medicines. To avoid this, a minimum interval of 5 minutes should be observed between different eye drop applications. AKANTIOR should always be administered last in the sequence of eye drops, ensuring that the antiparasitic agent has maximum contact time with the ocular surface.
Patients with Acanthamoeba keratitis frequently receive concomitant ophthalmic therapy, which may include topical corticosteroids (to manage inflammation), cycloplegic agents (to reduce pain from ciliary spasm), lubricating eye drops (to support the ocular surface), or topical antibiotics (if bacterial co-infection is suspected). While these combinations are commonly used in clinical practice, the decision to use corticosteroids alongside AKANTIOR should be made carefully by your ophthalmologist, as immunosuppressive agents may theoretically reduce the immune response against the parasite.
| Concomitant Medication | Type | Recommendation |
|---|---|---|
| Other eye drops (any type) | Practical interaction | Wait at least 5 minutes between drops; apply AKANTIOR last |
| Topical corticosteroid eye drops | Clinical consideration | Use with caution under specialist supervision; may reduce immune response to the parasite |
| Topical antibiotics | Commonly co-prescribed | No known interaction; maintain 5-minute interval; useful if bacterial co-infection present |
| Lubricating eye drops / Artificial tears | Supportive therapy | No known interaction; maintain 5-minute interval; helpful for ocular surface comfort |
| Cycloplegic agents (e.g. atropine) | Pain management | No known interaction; maintain 5-minute interval; commonly used for pain relief in AK |
| Contact lens solutions | Contraindicated | Do not wear contact lenses during treatment; lenses are a major risk factor for AK |
Because AKANTIOR is applied topically to the eye and systemic absorption is minimal, significant interactions with oral or injectable medications are not expected. However, it is still good practice to inform your healthcare team about all medications you are taking, including systemic immunosuppressive drugs, as these could potentially affect the body's ability to fight the Acanthamoeba infection.
What Is the Correct Dosage of AKANTIOR?
AKANTIOR treatment consists of two phases: an intensive phase (19 days) with gradually decreasing frequency, starting at 1 drop per hour (16 times daily), followed by a maintenance phase of 1 drop every 4 hours (4 times daily) until the infection clears. Always follow your doctor's instructions exactly.
Always use AKANTIOR exactly as your doctor has told you. If you are not sure about anything, ask your doctor or pharmacist. The recommended dose is 1 drop of AKANTIOR in the affected eye, following a carefully structured tapering schedule. The treatment is divided into two phases to ensure effective elimination of both the active trophozoite and dormant cyst forms of Acanthamoeba.
Intensive Treatment Phase (Days 1–19)
The intensive phase is critical for achieving high local concentrations of polihexanide to combat the acute infection. The dosing schedule progressively tapers as follows:
| Treatment Period | Frequency | Drops per Day | Key Notes |
|---|---|---|---|
| Days 1–5 | 1 drop every hour | 16 drops/day | During waking hours only; set reminders to maintain schedule |
| Days 6–12 | 1 drop every 2 hours | 8 drops/day | Continue consistent timing throughout waking hours |
| Days 13–19 | 1 drop every 3 hours | 6 drops/day | Continue even if symptoms improve |
Maintenance Treatment Phase (From Day 20 Onwards)
Following the intensive phase, treatment continues with a reduced frequency:
Maintenance Dosage
1 drop every 4 hours (4 times per day) in the affected eye. Continue until the cornea is no longer inflamed and there are no remaining signs of infection. Your ophthalmologist will determine when it is appropriate to discontinue treatment based on clinical examination and, where available, confocal microscopy findings.
The total duration of maintenance therapy varies from patient to patient. Some patients may require several weeks of maintenance treatment, while others with more resistant infections may need several months. It is essential to continue treatment for as long as your doctor prescribes, even if your symptoms improve, because Acanthamoeba cysts can persist in the cornea and may re-emerge if treatment is stopped prematurely.
How to Administer AKANTIOR Eye Drops
AKANTIOR is supplied in single-dose containers (also called unit-dose vials). Follow these steps carefully each time you administer the drops:
- Wash your hands thoroughly before handling the eye drops.
- Open the aluminium pouch containing the single-dose containers.
- Detach one single-dose container from the strip and return the remaining unused containers to the pouch.
- Open the container by twisting off the top portion (do not pull). Do not touch the tip after opening.
- Tilt your head back. Hold the open container upright and do not squeeze it yet.
- Gently pull down the lower eyelid of the affected eye with one finger to create a small pocket.
- Invert the container and hold the tip close to your eye without touching the eye or eyelid. Squeeze gently to release only one drop, then let go of the eyelid.
- Close your eyes and press a finger against the inner corner of the affected eye (punctal occlusion). Hold for 2 minutes to enhance absorption and reduce systemic drainage.
- Discard the container immediately after use. Do not re-use, even if some solution remains.
Missed Dose
If you forget to apply a dose, administer it as soon as you remember and then continue with the next dose at the regular scheduled time. Do not use a double dose to make up for a missed one. Maintaining consistent dosing is important for treatment effectiveness, so consider setting alarms or reminders, especially during the intensive phase when hourly administration is required.
Overdose
If you accidentally apply more than one drop or use AKANTIOR more frequently than prescribed, it is unlikely to cause serious harm. Simply continue with your next dose at the normally scheduled time. If you are concerned or experience unusual symptoms, contact your doctor or pharmacist for advice. In the event of accidental ingestion, seek medical advice immediately, although significant toxicity from oral ingestion of the small amount contained in eye drop containers is not expected.
Continue using AKANTIOR for as long as your doctor prescribes. Stopping treatment too early, even if you feel better, may allow dormant Acanthamoeba cysts to reactivate, leading to recurrence of the infection. Always discuss with your doctor before discontinuing treatment.
What Are the Side Effects of AKANTIOR?
The most common side effects of AKANTIOR are eye pain and red eyes (ocular hyperemia), affecting more than 1 in 10 users. Most side effects occur in the treated eye and are usually mild to moderate. Contact your doctor if you experience a severe eye reaction.
Like all medicines, AKANTIOR can cause side effects, although not everyone gets them. Most side effects reported during clinical use occur in the treated eye and are related to the local effects of the medicine and the underlying condition being treated. It is important to distinguish between side effects of the medication and symptoms of the underlying Acanthamoeba keratitis, which itself causes significant eye pain, redness, and visual disturbance.
Contact your doctor promptly if you experience any severe eye reaction, sudden worsening of vision, or symptoms that concern you. Below is a comprehensive overview of reported side effects organised by frequency.
Very Common Side Effects
May affect more than 1 in 10 users
- Eye pain — ranging from mild discomfort to stinging or burning sensation upon application
- Ocular hyperemia (red eyes) — increased blood flow to the conjunctiva causing visible redness
Common Side Effects
May affect up to 1 in 10 users
- Corneal perforation — damage to the corneal surface (may also be related to the underlying disease)
- Vision impairment — temporary reduction in visual acuity
- Ulcerative keratitis — inflammation or infection of the cornea with ulceration
- Corneal epithelial defects — damage to the outermost layer of the cornea
- Corneal infiltrates — immune response causing white deposits in the cornea
- Punctate keratitis — small pits in the eye surface
- Lacrimation increased (watery eyes) — excessive tearing
- Conjunctival hyperemia — redness of the conjunctiva
- Eye inflammation — general inflammatory response in the eye
- Eye irritation — discomfort, stinging, or burning sensation
- Photophobia — uncomfortable sensitivity to light
- Conjunctival papillae — the inside of the eyelid becomes red, swollen, and irritated
- Eye pruritus (itching) — itchy sensation in or around the eye
- Eye discharge — mucous or watery discharge from the eye
- Eyelid oedema — swelling of the eyelids
- Foreign body sensation — feeling as though something is in the eye
- Eye discomfort — general unpleasant sensation in the eye
- Dry eye — reduced tear production or increased evaporation
- Conjunctivitis — inflammation of the outermost layer of the eye
- Eye infection — secondary infection of the eye
- Condition aggravated — worsening of the underlying condition
- Product intolerance — allergic reaction to the medicine
- Application site reactions — pain, discomfort, or itching at the site of application
- Persistent epithelial defect — ongoing loss of the outermost corneal layer following injury
- Toxicity to various agents — sensitivity to the medicine or its components
- Need for corneal transplantation — in cases of severe corneal damage, a transplant may be required
It is important to understand that many of the common side effects listed above, particularly corneal perforation, corneal epithelial defects, and the need for corneal transplantation, may also be consequences of the underlying Acanthamoeba keratitis itself rather than direct effects of the medication. Acanthamoeba keratitis is inherently a destructive disease, and some degree of corneal damage may occur despite appropriate treatment.
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority (e.g., the MHRA in the UK, the EMA in the EU). By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store AKANTIOR?
Store AKANTIOR at room temperature with no special storage requirements. Once the aluminium pouch is opened, use the single-dose containers within 28 days. Each individual container must be used immediately after opening and discarded afterwards.
Proper storage of AKANTIOR is essential to maintain the sterility and effectiveness of the medicine. Follow these storage guidelines carefully:
- Keep out of the sight and reach of children at all times.
- No special storage conditions are required — store at room temperature. There is no need for refrigeration.
- Do not use after the expiry date printed on the carton and pouch after "EXP". The expiry date refers to the last day of the indicated month for the unopened product.
- After opening the dose pouch: The single-dose containers must be used within 28 days. After this period, any remaining unused containers must be discarded, even if they appear intact.
- After opening a single-dose container: Use the contents immediately. Any remaining solution in the opened container must be discarded. Do not save opened containers for later use, as sterility cannot be guaranteed once the container has been opened.
- Disposal: Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. These measures help to protect the environment.
AKANTIOR single-dose containers are supplied as strips of 5 sealed units enclosed in an aluminium/polyester/polyethylene dose pouch and packaged in a carton. Available pack sizes include 20 single-dose containers, 30 single-dose containers, and a multipack of 120 (4 packs of 30). Not all pack sizes may be marketed in every country.
What Does AKANTIOR Contain?
AKANTIOR contains polihexanide 0.8 mg/mL as the active ingredient. The inactive ingredients are sodium phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, and purified water. It is a clear, colourless, preservative-free solution.
Understanding the composition of your medicine helps you identify potential allergens and understand how the formulation is designed. AKANTIOR is a clear and colourless solution supplied in preservative-free single-dose low-density polyethylene containers.
| Ingredient | Role | Details |
|---|---|---|
| Polihexanide (PHMB) | Active ingredient | 0.8 mg per mL (0.08%); antiparasitic biguanide |
| Sodium phosphate monohydrate | Buffer | Maintains pH stability of the solution |
| Disodium hydrogen phosphate dodecahydrate | Buffer | Maintains pH stability of the solution |
| Sodium chloride | Tonicity agent | Adjusts osmolarity to match natural tears |
| Purified water | Solvent | Vehicle for the solution |
The phosphate buffer system in AKANTIOR requires a note of caution: in patients with severely damaged corneas, phosphate may in very rare cases cause cloudy patches on the cornea due to calcium deposition (corneal calcification). Each drop of AKANTIOR contains approximately 0.37 mg of phosphate, corresponding to a concentration of 10.66 mg/mL. Your ophthalmologist will be aware of this potential complication and will monitor your cornea accordingly during treatment.
AKANTIOR does not contain any preservatives, which is an important advantage for a medicine that requires prolonged and frequent administration. Preservatives commonly found in multi-dose eye drops, such as benzalkonium chloride, can cause cumulative toxicity to the corneal epithelium, which would be particularly harmful in eyes already compromised by Acanthamoeba keratitis. The preservative-free single-dose container format eliminates this concern.
Frequently Asked Questions About AKANTIOR
AKANTIOR is used to treat Acanthamoeba keratitis, a rare but serious parasitic infection of the cornea (the clear front surface of the eye). Acanthamoeba is a microscopic organism commonly found in water and soil that can infect the eye, particularly in contact lens wearers. The infection causes severe eye pain, redness, light sensitivity, and can lead to vision loss if not treated promptly. AKANTIOR is the first medicine specifically approved for this condition in the European Union and is used in adults and children aged 12 years and older.
AKANTIOR treatment involves two phases. The intensive phase lasts 19 days, starting with hourly drops (16 times per day) for the first 5 days, reducing to every 2 hours (8 times per day) for days 6–12, and then every 3 hours (6 times per day) for days 13–19. The maintenance phase follows, with drops every 4 hours (4 times per day) until the infection has completely cleared. The total treatment duration varies depending on how quickly the infection responds, ranging from several weeks to several months. Your ophthalmologist will decide when to stop treatment based on clinical examination.
No, you should not wear contact lenses during treatment with AKANTIOR. Contact lens wear is the primary risk factor for developing Acanthamoeba keratitis, and wearing lenses during treatment could interfere with the medication's effectiveness, risk reinfection, and impede corneal healing. After your infection has fully resolved and your ophthalmologist has confirmed that treatment is complete, they will advise you on when (and whether) it is safe to return to contact lens wear. Strict hygiene practices will be essential going forward.
If you miss a dose, apply it as soon as you remember, then resume your regular dosing schedule. Do not apply a double dose to compensate for the missed one. During the intensive phase (especially the hourly dosing in the first 5 days), it can be helpful to set alarms on your phone or use a medication tracking app to maintain the schedule. Consistency is important for treatment success, but an occasional missed dose is unlikely to significantly impact the outcome. If you are frequently missing doses, discuss practical strategies with your healthcare team.
AKANTIOR contains polihexanide (PHMB), which fights Acanthamoeba through two complementary mechanisms. First, it damages the cell membrane of the parasite, causing the internal contents to leak out and the organism to be destroyed. Second, it prevents the parasite from copying its DNA by interfering with the enzymes needed for replication, which stops the parasite from growing and multiplying. This dual action is important because Acanthamoeba can exist in a highly resistant dormant form (cysts) in addition to its active feeding form (trophozoites), and effective treatment must target both.
AKANTIOR has not been studied in pregnant women, and as a precaution it is not recommended during pregnancy. It is also unknown whether polihexanide passes into breast milk, although systemic absorption from eye drops is expected to be very low. If you are pregnant, breastfeeding, or planning a pregnancy, discuss the risks and benefits with your doctor. In severe cases of Acanthamoeba keratitis where treatment is urgently needed to preserve vision, your doctor may decide that the benefits of treatment outweigh the theoretical risks.
References and Sources
- European Medicines Agency (EMA). AKANTIOR (polihexanide) — European Public Assessment Report (EPAR). EMA/2024. Available at: ema.europa.eu/en/medicines/human/EPAR/akantior
- Dart JKG, Saw VPJ, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. American Journal of Ophthalmology. 2009;148(4):487–499.e2. doi:10.1016/j.ajo.2009.06.009
- Lorenzo-Morales J, Khan NA, Walochnik J. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite. 2015;22:10. doi:10.1051/parasite/2015010
- Maycock NJR, Jayaswal R. Update on Acanthamoeba keratitis: diagnosis, treatment, and outcomes. Cornea. 2016;35(5):713–720. doi:10.1097/ICO.0000000000000804
- Lalitha P, Lin CC, Srinivasan M, et al. Acanthamoeba keratitis in South India: a longitudinal analysis of epidemics. Ophthalmology. 2012;119(12):2464–2470. doi:10.1016/j.ophtha.2012.06.029
- Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. American Journal of Ophthalmology. 2008;145(1):130–135. doi:10.1016/j.ajo.2007.08.040
- Alkharashi M, Lindsley K, Law HA, DeCroos FC. Medical interventions for Acanthamoeba keratitis. Cochrane Database of Systematic Reviews. 2015;(2):CD010792. doi:10.1002/14651858.CD010792.pub2
- Royal College of Ophthalmologists. Guidelines for the management of Acanthamoeba keratitis. London: RCOphth; 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd list. Geneva: WHO; 2023.
- Siddiqui R, Khan NA. Biology and pathogenesis of Acanthamoeba. Parasites & Vectors. 2012;5:6. doi:10.1186/1756-3305-5-6
About the Medical Editorial Team
This article has been researched, written, and medically reviewed by the iMedic Medical Editorial Team, comprising licensed physicians and pharmacists with expertise in ophthalmology, infectious disease, and clinical pharmacology.
Medical Review Board
Independent panel of specialist physicians who review all medication articles for accuracy, completeness, and adherence to evidence-based medicine principles.
Evidence Standards
All content follows the GRADE evidence framework and is based on EMA assessment reports, peer-reviewed research, WHO guidelines, and regulatory agency documentation.
Last fact-checked: . This article is reviewed and updated regularly to reflect the latest clinical evidence and regulatory information.